Category Medicine and Healthcare
Press Release
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024 As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register Read More
Press Release
Interactive Strength Inc. (Nasdaq:TRNR) Reports Second Quarter 2025 Results; Increases 2025 Pro Forma Revenue Guidance to More Than $80M
Company Reports Quarterly Revenue of $1.2 Million; Net Loss and Loss per Diluted Share of $2.2 Million and $2.13 Quarterly Adjusted EBITDA Loss of $1.7 Million Reflects 40% YOY Improvement TRNR held 29.6 Million FET tokens as of June 30, 2025 and 67.4 Million FET tokens as of August 13, 2025, with a value in excess of $50 million, representing the largest publicly traded AI-focused Digital Asset Treasury Stockholders' Equity Was $16.3 Million at Quarter End 2025 Pro Forma Revenue Guidance Increased to more than $80 Million, driven by Sportstech's Stronger-Than-Expected Performance, and Fourth Quarter Profitability Guidance Reiterated Read More
Press Release
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial- - Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025 - Read More
Press Release
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 Read More
Press Release
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential 30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™'s four bold flavors As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company's new E-commerce website Read More
Press Release
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors Read More
Press Release
Dr. Peter Talisse Joins Ankle & Foot Centers of America, Serving Peachtree City, Newnan, and Fayetteville
A fellowship-trained foot and ankle surgeon with expertise in reconstruction, sports injuries, and limb salvage, Dr. Talisse brings advanced care to three South Metro Atlanta locations. Read More
Press Release
IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1
Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology Read More
Press Release
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Click here to register Company plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025 Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register Read More
Press Release
MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025. Read More
Press Release
President Trump Signals Openness to Medical Cannabis-MMJ BioPharma Files Emergency Motion to DEA Administrator Terry Cole
MMJ BioPharma is taking its fight for FDA approved cannabis medicine directly to DEA Administrator Terry Cole, as President Trump signals openness to marijuana's medical benefits. After seven years of delays, MMJ is ready to launch clinical trials for Huntington's disease and Multiple Sclerosis- if the DEA finally issues its long overdue API Bulk manufacturing registration. Read More
Press Release
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate cancer), and newly added APVO455 - advancing a targeted, tumor-specific strategy uniquely engineered for safety, tumor specificity and clinical impact Mipletamig, continues to outperform benchmarks, trial enrollment continues $15.9 million raised in 2Q25, extending cash runway into late 4Q25 Read More
Press Release
Trump May Reclassify Marijuana - MMJ BioPharma To Escape The DEA's Seven Year Cannabis Trial Roadblock?
Trump said his administration will focus on research to unlock the medical uses of marijuana, and other priorities the marijuana industry has sought. However, will employees within the DEA continue trying to block President Trumps marijuana orders? Read More
Press Release
TERRY COLE FIX IT! DEA Blocks FDA Cannabis Trials While Contaminated Marijuana Floods State Markets
Terrance Cole's Choice: Reformer or Cover-Up Artist? New DEA Administrator Terrance Cole stands at a crossroads: Break rank, clean house, and restore the DEA's marijuana research credibility by approving MMJ BioPharma's application. Or protect the old guard's corruption-and go down as the next puppet in a failed prohibitionist machine. Quotes From Inside the Agency Reveal Systemic Corruption, Regulatory Negligence, and Public Health Betrayal. The DEA's war on cannabis research is not just a failure of policy-it's a failure of morality. Read More
Press Release
